文献速递神经肿瘤

5-氨基乙酰丙酸用于脑转移瘤荧光引导切除术的系统综述

Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review.
PubMed 文献 · J Neurooncol · 2022-11-12

本系统综述通过检索PubMed并遵循PRISMA指南,纳入10项研究共631例患者,评估5-氨基乙酰丙酸(5-ALA)荧光用于脑转移瘤切除术的效果。结果显示5-ALA荧光率在27.6%至86.9%之间,且在不同肿瘤类型之间及内部存在差异;没有研究得出5-ALA使用可改善手术结局或生存结局的结论。现有研究有限,不能确认5-ALA可改善切除范围或术后生存。

要点

  • 纳入10项研究共631例患者,60%为回顾性设计。
  • 脑转移瘤5-ALA荧光率范围为27.6%至86.9%,不同肿瘤类型间及内部存在差异。
  • 没有研究得出5-ALA使用可改善手术结局或生存结局的结论。

核心结论

  • 现有关于5-ALA荧光用于脑转移瘤的研究有限,不能确认其可改善切除范围或术后生存。
  • 荧光在不同肿瘤类型之间及内部存在差异。
  • 需要进一步研究以评估特定肿瘤是否可能从5-ALA荧光引导手术中获益,或改变给药方案或荧光定量是否可能影响术中实用性。

研究设计与样本

  • 系统综述,检索PubMed中涉及5-ALA与脑转移瘤的研究,遵循PRISMA指南筛选。
  • 共纳入10项研究,分析631例患者;其中60%的研究为回顾性设计。

主要发现

  • 纳入的脑转移瘤中,报告的5-ALA荧光率范围为27.6%至86.9%,在不同肿瘤类型之间及内部存在差异。
  • 没有研究得出5-ALA使用可改善手术结局或生存结局的结论。

局限性

  • 现有关于5-ALA荧光用于脑转移瘤的研究有限。
  • 没有研究得出5-ALA使用可改善手术结局或生存结局的结论。
  • 荧光在不同肿瘤类型之间及内部存在差异。
  • 需要进一步研究以评估特定肿瘤是否可能从5-ALA荧光引导手术中获益,或改变给药方案或荧光定量是否可能影响术中实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors. METHODS: PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes. RESULTS: Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use. CONCLUSIONS: Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shah HA, Leskinen S, Khilji H, et al. Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review. J Neurooncol. 2022. PMID: 36370294. doi:10.1007/s11060-022-04188-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。